中期因子在相关疾病发病机制和治疗中的研究进展

中期因子(Midkine,MK),是一种分泌型肝素结合性生长因子,具有促进细胞有丝分裂、诱导细胞恶化、促进微血管生成、抑制细胞凋亡、促进炎症介质趋化、促纤溶等功能特点;经研究发现,当机体处于健康状态时中期因子除了肾脏及小肠上皮少量表达,其他部位极少表达,但机体出现疾病时,中期因子在体内的表达明显增多,如在多种恶性肿瘤、动脉粥样硬化、各类炎症、糖尿病肾病、高血压及COPD等疾病中均监测到中期因子的高表达,进一步研究发现上述疾病的发生发展与中期因子的功能特点密切相关;近年有学者利用MK在疾病发生发展中的功能特点对疾病进行治疗,特别是MK在肿瘤领域的治疗已成为研究热点,本文结合国内外的最新研究现状就MK与相关疾病的发病机制及治疗作一简要概述,并提出进一步研究的设想。

Research Progress of Midkine in the Related Diseases Pathogenesis and Treatment

ABSTRACT: Midkine(MK), a secreted heparin-binding growth factor, has the characteristics of promoting cell mitosis, inhibiting cell apoptosis, promoting angiogenesis, inducing cell deterioration, promoting chemotaxis of inflammatory mediators, promoting fibrinolysis, and the like, when the body is in a healthy state, MK is more expressed in the kidney and the small intestinal epithelium, and the other parts are very rarely expressed. The high expression of MK is monitored in the diseases such as hypertension and COPD, and further studies have shown that the development of the above-mentioned diseases is closely related to the functional characteristics of MK; In recent years, the functional characteristics of the MK in the development of the disease are used to treat the diseases, In particular, the treatment of MK in the field of tumor has become a hot spot. In this paper, based on the latest research status at home and abroad, this paper makes a brief overview of the pathogenesis and treatment of MK and related diseases, and puts forward some ideas.